Diagnostic Delay in Crohn's Disease Is Associated With a Complicated Disease Course and Increased Operation Rate

[1]  G. Rogler,et al.  Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease , 2012, Inflammatory bowel diseases.

[2]  F. Shanahan,et al.  Irritable Bowel Syndrome–Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation? , 2010, The American Journal of Gastroenterology.

[3]  P. V. van Rheenen,et al.  Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis , 2010, BMJ : British Medical Journal.

[4]  L. Peyrin-Biroulet,et al.  Early Crohn disease: a proposed definition for use in disease-modification trials , 2010, Gut.

[5]  F. Shanahan,et al.  Irritable Bowel Syndrome – Type Symptoms in Patients With Infl ammatory Bowel Disease : A Real Association or Refl ection of Occult Infl ammation ? , 2010 .

[6]  J. Cangemi,et al.  Immunomodulators Are Associated With a Lower Risk of First Surgery Among Patients With Non-Penetrating Non-Stricturing Crohn's Disease , 2009, The American Journal of Gastroenterology.

[7]  J. Markowitz.  Early Inflammatory Bowel Disease: Different Treatment Response to Specific or All Medications? , 2009, Digestive Diseases.

[8]  B. Burnand,et al.  Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). , 2009, International journal of epidemiology.

[9]  M. Vatn,et al.  A characterization in childhood inflammatory bowel disease, a new population-based inception cohort from South-Eastern Norway, 2005–07, showing increased incidence in Crohn's disease , 2009, Scandinavian journal of gastroenterology.

[10]  P. Rutgeerts,et al.  Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. , 2008, Gastroenterology.

[11]  I. Ordás,et al.  Are we giving biologics too late? The case for early versus late use. , 2008, World journal of gastroenterology.

[12]  M. Sans,et al.  Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. , 2008, World journal of gastroenterology.

[13]  R. Baldassano,et al.  Presentation and Disease Course in Early- Compared to Later-Onset Pediatric Crohn's Disease , 2008, The American Journal of Gastroenterology.

[14]  A. Griffiths,et al.  Effect of early immunomodulator use in moderate to severe pediatric Crohn disease , 2008, Inflammatory bowel diseases.

[15]  N. Talley,et al.  Value of Different Diagnostic Criteria for the Irritable Bowel Syndrome Among Men and Women , 2008, Journal of clinical gastroenterology.

[16]  A. Schoepfer,et al.  Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies , 2008, Inflammatory bowel diseases.

[17]  M. Vatn,et al.  Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  William J. Tremaine,et al.  Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000 , 2007, Inflammatory bowel diseases.

[19]  A. Frigessi,et al.  Incidence and clinical presentation of IBD in children: Comparison between prospective and retrospective data in a selected Norwegian population , 2006, Scandinavian journal of gastroenterology.

[20]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  G. Lichtenstein.  PRO: Maintenance Therapy Is Superior to Episodic Therapy , 2005, The American Journal of Gastroenterology.

[22]  R. Modigliani,et al.  A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. , 2005, Gastroenterology.

[23]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[24]  G. Lichtenstein.  Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. , 2005, The American journal of gastroenterology.

[25]  M. Russel,et al.  Has disease outcome in Crohn's disease changed during the last four decades? , 2004, Alimentary pharmacology & therapeutics.

[26]  F. Carbonnel,et al.  Long-Term Evolution of Disease Behavior of Crohn's Disease , 2002, Inflammatory bowel diseases.

[27]  J. Willis,et al.  Distinct inflammatory mechanisms mediate early versus late colitis in mice. , 2002, Gastroenterology.

[28]  J. Belaiche,et al.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease , 2001, Gut.

[29]  S. Targan,et al.  Identification of a prodromal period in Crohn's disease but not ulcerative colitis , 2000, American Journal of Gastroenterology.

[30]  P. Munkholm,et al.  Disease activity courses in a regional cohort of Crohn's disease patients. , 1995, Scandinavian journal of gastroenterology.

[31]  L. Melton,et al.  Diagnostic value of the Manning criteria in irritable bowel syndrome. , 1990, Gut.

[32]  H. Mekhjian,et al.  Clinical features and natural history of Crohn's disease. , 1979, Gastroenterology.